Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 2006

View Archived Issues

Enrollment completed in second phase III study of Sanctura XR

Novelos files IND for NOV-205 for chronic hepatitis C

Ono and Santen enter ophthalmic licensing agreement for ONO-6126

New phase Ib/II trial studies PXD-101 with Velcade in multiple myeloma

Pixantrone combination regimen shown effective in relapsed aggressive NHL

Second phase III study begins for Viprinex in acute ischemic stroke

Orphan drug designation for HD-02 for Huntington's disease

Arius licenses antibody to Genentech

Ceragenix compounds inhibit angiogenesis in in vitro tests

pSivida offers progress report

GammaCan holds pre-IND meeting with FDA for VitiGam

VistaGen and Cato BioVentures sign strategic agreement for CNS products

Astellas licenses antihuman osteopontin antibodies

Encouraging preclinical results for oral NNZ-2566

Chemoprotective effects of DMU-135, a new anticancer prodrug

Novel therapeutic agents for respiratory disorders disclosed in recent patents

Novel 5-HT7 receptor antagonists prepared and tested at Esteve

New monoclonal TCR technology for cancer-specific immunotargeting

Flovent HFA approved for asthmatic children aged 4-11 years

BLA submission for FluLaval

Taxotere approved for advanced stomach cancer

New P2X7 receptor antagonists emerge from Abbott R&D

Novel immunomodulator holds promise for treatment of allergic inflammation

Promising preclinical results with novel oral insulin developed by Terumo

Cytotoxic treatment could be used to fight H5N1 infection

Glycan microarray analysis reveals possible route for avian influenza virus to adapt to humans

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...